Table 1 Baseline characteristics of the included studies
From: Chemical sphincterotomy in posthemorrhoidectomy pain relief: a meta-analysis
Studies | Year | Country | Study Design | Age (mean ± SD) | Sex (man: woman, n) | Operation | Primary Outcome | Specific Interventions | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Â | Control | Observation | Control | Observation | Â | Â | Â | |||
Sunandan Yadav | 2018 | India | RCT | 50.40 ± 13.78 | 51.06 ± 12.92 | 23:7 | 22:8 | Milligan-Morgan | VAS in 6 h and day1,2,7 | OG: 2% diltiazem ointment CG: placebo Admn: 3 times daily × 1 week |
Ralph Silverman | 2005 | USA | RCT | 45.00 ± 5.00 | 44.00 ± 16.00 | 5:4 | 2:7 | NM | VAS in day1-7 | OG: 2% diltiazem ointment CG: placebo Admn: 3 times daily × 1 week |
H. A. Amoli | 2009 | Iran | RCT | 52.12 ± 12.99 | 54.13 ± 19.22 | 13:4 | 14:2 | Milligan-Morgan | VAS in day1-7 | OG: 2% diltiazem ointment CG: placebo Admn: 3 times daily × 1 week |
Sunil Suchdev | 2014 | Pakistan | RCT | 39.85 ± 14.91 | 37.73 ± 14.90 | 34:6 | 31:9 | Milligan-Morgan | VAS in day2 | OG: 2% diltiazem ointment CG: placebo Admn: NM |
U. RodrÃguez-Wong | 2016 | Mexico | RCT | 44.77 | 46.59 | 6:11 | 9:8 | Ferguson | VAS in day1-3 | OG: 2% diltiazem ointment CG: placebo Admn: 3 times daily × 3 days |
Sepideh Vahabi | 2019 | Iran | RCT | NM | NM | NM | NM | Milligan-Morgan | VAS in 6,12,18 and 24 h | OG: 0.2% GTN ointment CG: placebo Admn: 3 times daily × 1 week |
Harry J. Wasvary | 2001 | USA | RCT | 49 | 54 | 12:8 | 8:11 | Ferguson | VAS in day1-7 | OG: 0.2% GTN ointment CG: placebo Admn: 3 times daily × 1 week |
Francesco Saverio Mari | 2013 | Italy | RCT | 48.3 ± 8.6 | 48.7 ± 9 | 13:7 | 15:6 | Stapled Hemorrhoidopexy | VAS in day1,2,7,14 | OG: 0.4% GTN ointment CG: 2.5% lidocaine Admn: twice daily × 2 weeks |
Hasan Karanlik | 2009 | Turkey | RCT | 36.6 ± 10.4 | 34.4 ± 10.8 | 16:14 | 15:15 | Ferguson | VAS in day1,3,7 | OG: 0.2% GTN ointment CG: placebo Admn: twice daily × 2 weeks |
G. Di Vita | 2004 | Italy | RCT | 40.6 ± 18 | 35 ± 20 | 8:7 | 9:6 | Milligan-Morgan | VAS in day1-7 | OG: 0.2% GTN ointment CG: placebo Admn: 3 times daily × 2 weeks |
Do Yeon Hwang | 2003 | Korea | RCT | NM | NM | NM | NM | NM | VAS in day1-3 | OG: 0.2% GTN ointment CG: placebo Admn: 3 times daily × 3 weeks |
Rosalia Patti | 2005 | Italy | RCT | 36 ± 18 | 33 ± 15 | 8:7 | 9:6 | Milligan-Morgan | VAS in day1,3,7 | OG: 0.2% GTN ointment CG: placebo Admn: 3 times daily × 15 days |
Siripong Sirikurnpiboon | 2020 | Thailand | RCT | 42.23 ± 12.78 | 41.21 ± 13.94 | 23:20 | 21:18 | Ferguson | VAS in 12 and 24 h | OG: 30 units of BTX CG: placebo Admn: Injection once after surgery |
B. Singh | 2009 | UK | RCT | 52.5 ± 11.4 | 52.9 ± 9.2 | 13:4 | 11:4 | Milligan-Morgan | VAS in day1-14 | OG: 150 units of BTX CG: placebo Admn: Injection once after surgery |